Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) – Cantor Fitzgerald equity researchers increased their earnings per share (EPS) estimate for fiscal 2022 for Biohaven Pharmaceutical in a research report released to customers and investors on Monday, September 13. Cantor Fitzgerald analyst C. Duncan now predicts the company will post earnings of ($ 9.43) per share for the year, up from its previous forecast of ($ 9.68). Cantor Fitzgerald currently has an “Overweight” rating and a target price of $ 165.00 on the stock.
A number of other equity research analysts have also recently published reports on BHVN. HC Wainwright raised its price target for Biohaven Pharmaceutical shares from $ 111.00 to $ 135 and gave the company a “buy” rating in a report released Thursday, July 8. Zacks Investment Research downgraded Biohaven Pharmaceutical shares from a “strong sell” rating to a “hold” rating and set a price target of $ 123.00 for the company in a report released on Monday, July 12. . UBS Group downgraded Biohaven Pharmaceutical’s shares from a “buy” rating to a “neutral” rating and increased its price target for the company from $ 108.00 to $ 109.00 in a report released on Tuesday 10 August. Cowen raised his price target for Biohaven Pharmaceutical shares from $ 90.00 to $ 130.00 and gave the company an “outperformance” rating in a report released on Wednesday, July 7. Finally, Canaccord Genuity raised its target price on Biohaven Pharmaceutical shares from $ 101.00 to $ 150.00 and assigned the company a “buy” rating in a research note on Tuesday, August 3. Three analysts rated the stock with a conservation rating and nine gave the stock a buy rating. According to MarketBeat, Biohaven Pharmaceutical currently has a consensus rating of “Buy” and a consensus price target of $ 124.27.
BHVN stock opened at $ 135.34 on Wednesday. Biohaven Pharmaceutical has a 52 week low of $ 57.70 and a 52 week high of $ 139.50. The company has a 50-day moving average of $ 124.29 and a two-hundred-day moving average of $ 95.81. The stock has a market cap of $ 8.85 billion, a price-to-earnings ratio of -9.44 and a beta of 1.03. Biohaven Pharmaceutical (NYSE: BHVN) last released its results on Sunday, August 8. The company reported ($ 3.23) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($ 2.77) of ($ 0.46). The company posted revenue of $ 92.93 million for the quarter, compared to analysts’ expectations of $ 85.85 million. Biohaven Pharmaceutical’s revenue increased 858.3% year-on-year. In the same quarter of last year, the company made earnings per share ($ 2.55).
A number of large investors have recently bought and sold shares of BHVN. Thrivent Financial for Lutherans increased its position in Biohaven Pharmaceutical by 185.1% in the second quarter. Thrivent Financial for Lutherans now owns 1,416,890 shares of the company valued at $ 137,552,000 after purchasing an additional 919,951 shares in the last quarter. BlackRock Inc. increased its holdings of shares of Biohaven Pharmaceutical by 24.0% during the second quarter. BlackRock Inc. now owns 4,691,578 shares of the company valued at $ 455,460,000 after purchasing an additional 908,024 shares in the last quarter. Janus Henderson Group PLC acquired a new equity interest in Biohaven Pharmaceutical during the first quarter valued at approximately $ 49,082,000. Glenview Capital Management LLC acquired a new equity interest in Biohaven Pharmaceutical during the first quarter valued at approximately $ 31,345,000. Finally, Armistice Capital LLC increased its stake in Biohaven Pharmaceutical shares by 74.8% during the first quarter. Armistice Capital LLC now owns 1,000,000 shares of the company valued at $ 68,350,000 after purchasing an additional 428,000 shares in the last quarter. 92.14% of the shares are held by hedge funds and other institutional investors.
About Biohaven Pharma
Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company dedicated to the research and development of late-stage product candidates targeting neurological diseases, including rare diseases. It focuses on a pipeline of product candidates that represent mechanistic platforms, peptide receptor antagonists linked to the calcitonin gene, and glutamate modulators.
Featured article: What moving averages are used to define a golden cross?
This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Biohaven Pharmaceutical was not on the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here